FibroGen to Present at Two Upcoming Investor Conferences

SAN FRANCISCO, June 04, 2018 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced that management will participate in a Fireside Chat at the Jefferies 2018 Healthcare Conference in New York, NY on Thursday, June 7 at 2:30 p.m. Eastern Time, and will also participate in a Fireside Chat at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA, on Tuesday, June 12 at 2:40 p.m. Pacific Time.

A live audio webcast of the presentations will be available under the Investors section of the FibroGen website at www.fibrogen.com. The replay of the webcasts will be available for 14 days following the live presentation. Please connect to FibroGen’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About FibroGen
FibroGen, Inc., headquartered in San Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application currently under review in China by the State Drug Administration or SDA (formerly the China Food and Drug Administration). Roxadustat is in Phase 3 clinical development in the U.S. and Europe for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.

Contact
FibroGen, Inc.
Karen L. Bergman
Vice President, Investor Relations and Corporate Communications
1 (415) 978-1433
kbergman@fibrogen.com